Expert Ratings For Intellia Therapeutics
Portfolio Pulse from Benzinga Insights
In the last three months, 7 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target is $71.0, down 2.35% from the previous average. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Intellia Therapeutics, a gene editing company, faces financial challenges with declining revenue, negative net margin, and below-average ROE and ROA.
August 12, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Intellia Therapeutics has received mixed analyst ratings with an average 12-month price target of $71.0, down 2.35% from the previous average. The company faces financial challenges including declining revenue and negative net margins.
The mixed analyst ratings and slight decrease in the average price target indicate a neutral short-term impact on NTLA's stock price. The financial challenges such as declining revenue and negative margins are significant but already known factors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100